Abstract
The best time point to determine cure of chronic hepatitis C was explored in a retrospective analysis of five published trials of sofosbuvir–ribavirin with or without PEG-IFN. The authors conclude that SVR12 can be used effectively to determine ‘cure’ rates in trials and in clinical practice.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Continuity of Patient Care
-
Genotype
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / genetics
-
Humans
-
Interferon-alpha / therapeutic use
-
Polyethylene Glycols / therapeutic use
-
RNA, Viral / analysis
-
Recombinant Proteins / therapeutic use
-
Remission Induction
-
Ribavirin / therapeutic use
-
Sofosbuvir
-
Uridine Monophosphate / analogs & derivatives
-
Uridine Monophosphate / therapeutic use
Substances
-
Antiviral Agents
-
Interferon-alpha
-
RNA, Viral
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
Uridine Monophosphate
-
peginterferon alfa-2a
-
Sofosbuvir